HALO Halozyme
$91.35 -1.82%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Point at or drag across the chart to read a day. EOD data.
1D
-1.82%
YTD
+35.70%
P/E
25.65
P/B
162.13
ROE
180.6%
Div yield
—
Beta
0.61
Market cap
$10.6B
RSI (14)
20
Next earnings
Jan 26, 2027
Same sector · Health Care
Compare HALO with NVO and JNJ →Follow HALO in the AlfaCat app
Watchlist, price and earnings alerts, the chart offline. Free, no account, no ads.
The economy behind it · United States
Economy this week on BullDozer →GDP, % on year
2.1
Q3 2026
Inflation, %
3.7
Sep 2026
Unemployment, %
3.9
Oct 2026
10-yr yield, %
5.13
Oct 2026
From BullDozer, our sister site for country statistics (open sources: OECD, IMF, Eurostat, ILO). Full United States profile →
Previous session
close of Nov 20, 2026 · EOD, no live order bookOpen
$93.64
Close
$91.35
Day high
$93.64
Day low
$90.79
Volume
1.5M
Latest headlines
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Yahoo Finance · Nov 19
HALO Stock Hits Over 3-Month Lows, As German Court Overturns Temporary Ban On Merck’s Keytruda SC
Yahoo Finance · Nov 19
Halozyme Provides Update on German Preliminary Injunction Hearing
Yahoo Finance · Nov 19
Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
Yahoo Finance · Nov 12
Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
Yahoo Finance · Nov 12
Can You Make Money Off Halozyme Stock Now?
Yahoo Finance · Nov 11
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Nov 5, 2026 View → 8-K Nov 5, 2026 View → 8-K Sep 30, 2026 View → 8-K Sep 22, 2026 View → 8-K Sep 18, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell HALO. Try it in the Lab to size a position and see the risk.